Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Structure-activity relationships for 2-substituted imidazoles as alpha 2-adrenoceptor antagonists.

J M Caroon, R D Clark, A F Kluge

    Journal of Medicinal Chemistry
    |June 1, 1982
    PubMed
    Summary

    Researchers developed novel imidazole compounds to block alpha-2 adrenoceptors. Compound 13 showed high selectivity, entering the central nervous system and selected for antidepressant clinical trials.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Evaluation of QSAR models for predicting mutagenicity: outcome of the Second Ames/QSAR international challenge project.

    SAR and QSAR in environmental research·2023
    Same author

    Recent Progress in the Identification of the X-Linked Infantile Spinal Muscular Atrophy (<i>Xl-SMA</i>) Gene: Implications for Neuronal Apoptosis.

    TheScientificWorldJournal·2018
    Same author

    Silencing Agrobacterium oncogenes in transgenic grapevine results in strain-specific crown gall resistance.

    Plant cell reports·2013
    Same author

    Caudal block anesthesia and the general practitioner.

    Journal of the Medical Association of the State of Alabama·2010
    Same author

    Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain.

    Diabetes, obesity & metabolism·2010
    Same author

    Comparative properties of the dopamine transport complex in dog and rodent brain: striatal [(3)H]GBR12935 binding and [(3)H]dopamine uptake.

    Neurochemistry international·2010

    Area of Science:

    • Pharmacology
    • Medicinal Chemistry
    • Neuroscience

    Background:

    • Adrenoceptors, specifically alpha-1 and alpha-2, play critical roles in regulating physiological functions.
    • Selective modulation of these receptors is a key strategy in developing novel therapeutics.
    • Imidazole derivatives have shown potential as modulators of adrenoceptor activity.

    Purpose of the Study:

    • To synthesize and evaluate a series of 2-[(1,4-benzodioxan-2-yl)alkyl]imidazoles.
    • To determine the alpha-2 and alpha-1 adrenoceptor blocking activity and selectivity of these compounds.
    • To identify lead compounds for further development, particularly as potential antidepressant agents.

    Main Methods:

    • Synthesis of a series of 2-[(1,4-benzodioxan-2-yl)alkyl]imidazoles.

    Related Experiment Videos

  • In vitro evaluation of receptor antagonism using isolated rat vas deferens preparations.
  • Assessment of presynaptic (alpha-2) and postsynaptic (alpha-1) adrenoceptor activity.
  • Determination of lipophilicity (log D) to predict central nervous system penetration.

    • Main Results:

    • Several compounds were synthesized and tested for their adrenoceptor blocking effects.
    • 1-Ethyl-2-[(1,4-benzodioxan-2-yl)methyl]imidazole (compound 13) emerged as the most potent and selective alpha-2 adrenoceptor antagonist.
    • Compound 13 exhibited minimal to no alpha-1 adrenoceptor antagonist activity.
    • The lipophilicity of compound 13 (log D = 2.31) suggests good potential for central nervous system entry.

    Conclusions:

    • The synthesized imidazole derivatives demonstrate varying degrees of alpha-2 and alpha-1 adrenoceptor antagonism.
    • Compound 13 represents a highly selective alpha-2 adrenoceptor antagonist with favorable pharmacokinetic properties for CNS penetration.
    • Compound 13 was identified as a promising candidate for clinical investigation as an antidepressant medication.